Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Energy Bull 2X Shares ETF
ERX
VanEck Semiconductor ETF
SMH
4
The Technology Select Sector SPDR® Fund
XLK
5
Invesco Solar ETF
TAN
US Stock MarketDetailed Quotes
Nanobiotix (NBTX)
- 45.965
- -3.515-7.10%
Trading May 19 14:42 ET
2.23BMarket Cap-78.84P/E (TTM)
46.060High44.010Low58.05KVolume45.930Open49.480Prev Close2.61MTurnover0.19%Turnover RatioLossP/E (Static)48.50MShares57.14052wk High-22.64P/B1.43BFloat Cap3.81052wk Low--Dividend TTM31.14MShs Float57.140Historical High--Div Yield TTM4.14%Range %1.750Historical Low44.950Avg Price1Lot Size
NBTX Stock Chart
Real-Time
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
NBTX Orderflow
Unit: --
NBTX Orderflow Trend
IntradayDayWeekMonth
No Data
Nanobiotix (NBTX) News
XP Posts Downbeat Q1 Earnings, Joins Akamai Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Nanobiotix Price Target Raised to EUR 60 From EUR 34 at H.C. Wainwright
Express News | Reported Sunday, Nanobiotix CONVERGE Phase 2 Data Shows JNJ-1900 Achieves 100% Disease Control Rate In Stage 3 Inoperable NSCLC Patients
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Guggenheim Maintains Nanobiotix(NBTX.US) With Buy Rating, Maintains Target Price $36
Nanobiotix (NBTX) Stock Forum
$Nanobiotix (NBTX.US)$ Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.12) per share. This is a 76 percent increase over losses of $(0.50) per share from the same period last year. The company reported $30.202 million in sales this quarter. This is a 202.00 percent increase over sales of $10.001 million the same period last year.
1
$Nanobiotix (NBTX.US)$ NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
GlobeNewswire
7m
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1
63% (26/41) disease control rate ("DCR") and 37% (15/41) objective response rate ("ORR") in evaluable anti-PD-1 naïve pat...
GlobeNewswire
7m
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1
63% (26/41) disease control rate ("DCR") and 37% (15/41) objective response rate ("ORR") in evaluable anti-PD-1 naïve pat...
$Nanobiotix (NBTX.US)$ $Aptevo Therapeutics (APVO.US)$ get over there major professionals getting in
1
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)